Clinical Trial Update: Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida [Phase 1]

View source ↗

Summary

Phase 1 safety and immunogenicity study of the recombinant NDV-3 vaccine targeting Staphylococcus aureus and Candida infections has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Candidiasis
• Staphylococcal Infections

Drugs mentioned

• NDV-3

Snippet

Sponsor: NovaDigm Therapeutics, Inc. | Conditions: Staphylococcal Infections, Candidiasis | Phase 1 | Status: COMPLETED